"description","rationale","uuid:ID","label","id","name"
"The main design for the study","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","d0174d4c-f3d0-4e03-bf62-fad935eefb91","","StudyDesign_1","Study Design 1"
